| Abstract Objective To understand the incidence, mortality and survival of malignant tumors in Xiamen City, so as to provide reference for policy formulation. Method The data relating to the incidence and mortality of malignant tumors in Xiamen was collected from the Tumor Registration Information Direct Reporting Platform of Fujian Province to calculate the crude rate, age-standardized rate (ASR) by Chinese population , cumulative rate and truncated rate. The survival rate was analyzed by Period Analysis method. Results: In 2020, the reported incidence rate of malignant tumors in Xiamen residents was 350.46/105. The ASR in China, the cumulative rate between 0 and 74 years old, and the truncated rate of incidence between 35 and 64 years old were 275.12/105, 29.70%, 477.37/105, respectively. The top five cancers of incidence were: lung cancer, breast cancer, thyroid cancer, colorectal cancer, and liver cancer. The incidence of malignant tumor in male was higher than that in female(the ASR in China: 280.14 /105 VS 271.45/105). The mortality rate of malignant tumors was 150.62/105. The ASR in China, the cumulative rate between 0 and 74 years old,, and the truncated rate between 35 and 64 years old of death were 109.62/105,12.27%, 160.38/105, respectively. The top five site of death were lung, liver, colorectum, esophagus, and stomach. The mortality of malignant tumor in male 205.22/105 was much higher than that in female 98.02/105 (the ASR in China: 155.01 /105 VS 69.11/105). The 5-year observed survival rate (OS), relative survival rate (RS) and age-standardized relative survival rate (ARS) were 53.09% (95%CI: 51.80-54.36), 56.30% (95%CI:54.94-57.65) and 48.14% (95%CI:46.67-49.64), respectively. The 5-year ARS was lower in male than that in female (40.23% VS 57.75%). Conclusion: The comprehensive diagnosis and treatment level of malignant tumors in Xiamen is in the middle level of the country, but the incidence rate is high. Prevention and control should be strengthened, focusing on the growth trend of thyroid cancer, lung cancer, breast cancer, colorectal cancer and so on. |
